New Jersey Enacts “Magic Mushrooms” Psilocybin Behavioral Health Access and Therapy Law
Last week, New Jersey passed a bill, allocating six million dollars to the creation of three pilot psilocybin programs. Psilocybin, also know as “magic mushrooms” has been studied for treatment resistant depression, addiction, end of life anxiety, PTSD, OCD, and other mental health struggles, often with very positive results. January 20th, 2026, the outgoing Governor Murphy, signed the Psilocybin Behavioral Health Access and Service Act, which allocates six million dollars to three chosen hospitals in New Jersey. These hospitals will offer psilocybin assisted therapy following the protocols of previously successful FDA approved studies. These pilot programs will emphasize careful attention to medical and psychiatric screening, intentional use for mental health disorders, and therapy support around preparing and integrating the psychedelic experience. It should be noted, that the bill is in no way legalizing the recreational use of psilocybin. Although this is a big step for New Jersey, which is way ahead of its neighbor, Pennsylvania, many were hoping for a more expansive program. The pilot program approved will only use synthetic psilocybin, is in a hospital setting, and data will be collected over a two year period and reviewed by an 11 member committee – The Psychedelic Therapy and Research Advisory Board – before making further recommendations. However, this bill will make it easier for psilocybin to be studied, and have a responsible committee thoughtfully plan for the future in a careful and methodical way. The passing of this bill is due to the tireless work of veterans (Veterans Exploring Treatment Solutions (VETS), policy advocates, researchers, and patients brave enough to share their stories. Many are hopeful that New Jersey’s bill will encourage other states follow suit. And let’s not forget, the states before New Jersey, including Oregon, Colorado, and New Mexico, whose unique, creative programs are creating access to psilocybin treatment. For more information on NJ’s bill S2283 and how it compares to other states, click here: “Did NJ really just legalize psilocybin?” Psychedelic medicine, such as psilocybin, LSD, DMT, MDMA, and Ibogaine, represent a new frontier in psychiatry. Interestingly, many of these compounds have been studied for more than one indication, ranging from depression (most common) to PTSD, anxiety, OCD, eating disorders, autism, grief, and more. Psilocybin is now in phase three trials, which is the final phase of FDA approval, and the results are seemingly positive so far. Many believe psilocybin may be FDA approved this year or next. But until then, on a federal level, psilocybin is illegal, and those with treatment refractory depression, living in Pennsylvania, are unable to access this incredible tool. For now, Voyage Healing, is fortunate to offer ketamine and Spravato®, legal medicines with psychedelic effects, that have strong evidence bases for treatment resistant depression. Like the other psychedelics, there is growing evidence that ketamine may treat a variety of mental health disorders, such as PTSD, OCD and addiction. However, the largest evidence base is for treatment resistant depression and suicidality. Spravato®, an FDA-approved nasal spray version of ketamine, also know as esketamine, is the only FDA-approved medicine with psychedelic effects. Spravato® is currently indicated for treatment resistant depression and major depression with suicidal ideation. Voyage Healing remains committed to supporting evidence-based treatments, including psychedelic medicine, which are gathering more research base each year in FDA-approved trials. Careful rollout of these therapeutic medicines, with attention to safety and a supportive container consisting of preparation, integration, and attention to set and setting, will be key to the Western’s world’s ability to successfully integrate these revolutionary treatments into our current frameworks.
Dr. Gail Serruya, MD, is a board-certified psychiatrist who earned her medical degree and completed her psychiatric residency at the University of Pennsylvania (UPenn). She received her specialized clinical training in Cognitive Behavioral Therapy at the Beck Institute, studying directly under Dr. Aaron Beck, the “Father of CBT.” She specializes in Interventional Psychiatry, including Ketamine and Spravato therapy.
